Table 2.
Univariate and multivariate analysis of factors associated with virological non suppression in CLWH on ART for a at least 6 months (N = 250)
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Factor | UOR (95% CI) | P value | AOR (95% CI) | P value |
| Sex of child | 0.004* | 0.041* | ||
| Male | ref | |||
| Female | 2.52 1.35–4.67 | 2.51 1.04–6.07 | ||
| Age category | 0.342 | 0.138 | ||
| < 5 years | 1.72 0.57–5.24 | 2.18 0.23–20.89 | ||
| 5 to < 10 years | 1.57 0.78 –3.17 | 2.84 1.01–8.05 | ||
| 10 to 15 years | ref | ref | ||
| CD4+ Immune suppression status at study recruitment | < 0.001* | < 0.001* | ||
| Severe | 9.03 3.08–26.51 | 24.93 4.92–126.31 | ||
| Advanced | 7.97 2.03–31.31 | 9.2 1.27–66.48 | ||
| Mild | 3.65 1.35–9.9 | 3.75 0.91–15.4 | ||
| None | ref | ref | ||
| TB treatment in the past | 0.122 | 0.006* | ||
| No | ref | ref | ||
| Yes | 1.67 0.87–3.18 | 4.95 1.58–15.5 | ||
| Current Drug | 0.231 | 0.005* | ||
| Efavirenz based | ref | ref | ||
| Nevirapine based | 1.79 0.9 – 3.52 | 7.93 2.26–27.86 | ||
| Second line drug | 0.86 0.15–4.86 | 1.02 0.09–11.8 | ||
| Pill count rate | 0.012* | 0.264 | ||
| Good adherence | ref | ref | ||
| Fair adherence | 0.3 0.1–0.93 | 0.43 0.11 – 1.69 | ||
| Poor adherence | 1.93 0.92–4.03 | 1.65 0.54 – 5.01 | ||
*: p < 0.05